Cargando…
Sodium–glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties
Autor principal: | Li, Hung‐Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926239/ https://www.ncbi.nlm.nih.gov/pubmed/32967051 http://dx.doi.org/10.1111/jdi.13413 |
Ejemplares similares
-
Sodium-Glucose
Cotransporter Inhibitors as Antidiabetic
Drugs: Current Development and Future Perspectives
por: Maccari, Rosanna, et al.
Publicado: (2022) -
Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
por: Sheu, Wayne H‐H
Publicado: (2020) -
Incidence of severe urinary tract infections not increased by initiating sodium–glucose cotransporter 2 inhibitors
por: Yokoyama, Hiroki
Publicado: (2020) -
Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019) -
Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)